Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients

This study reports the development activities for the Treatment Preference Myelodysplasia Questionnaires (TPMQ) for clinicians (mTPMQ), carers (cTPMQ), and patients (pTPMQ). These tools are intended to evaluate treatment preferences for patients with myelodysplastic syndromes (MDS). This was a non‐i...

Full description

Saved in:
Bibliographic Details
Published inEJHaem Vol. 5; no. 3; pp. 535 - 540
Main Authors Morlock, Robert, Fong, Chun, Castaldi, Francesco, Paine, Taliesha, Collett, Donna, Enjeti, Anoop
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.06.2024
John Wiley and Sons Inc
Wiley
Subjects
Caregivers
Clinical trials
Consent
FDA approval
Haematologic Malignancy ‐ Myeloid
hypomethylating agents
Interviews
Myelodysplastic syndrome
Myelodysplastic syndromes
Older people
Patients
Preferences
Questionnaires
Research ethics
treatment preference
Australia
United States > US
questionnaires
hypomethylating agents
myelodysplastic syndromes
treatment preference
Online AccessGet full text

Cover

More Information
Summary:This study reports the development activities for the Treatment Preference Myelodysplasia Questionnaires (TPMQ) for clinicians (mTPMQ), carers (cTPMQ), and patients (pTPMQ). These tools are intended to evaluate treatment preferences for patients with myelodysplastic syndromes (MDS). This was a non‐interventional, cross‐sectional qualitative interview study consisting of interviews with clinicians, patients, and those caring for patients with MDS. All participants were located in Australia and data were collected from qualitative mixed‐method interviews composed of concept elicitation and cognitive debriefing related to initial drafts of the questionnaires. Fifteen individuals participated in interviews (five from each group). Based on the concept elicitation portion of interviews, concepts of importance were classified and reasons for treatment preference were documented. From cognitive debriefing, the questionnaires were generally deemed to be clear and easy to understand. Participant input from both concept elicitation and cognitive debriefing portions was used to revise initial drafts of the questionnaires. The mTPMQ, cTPMQ, and pTPMQ were developed with direct input from clinicians, patients, and caregivers to assess the key concepts of interest related to the preference for the treatment of MDS and are ready to be used and evaluated further in clinical trials.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2688-6146
2688-6146
DOI:10.1002/jha2.930